Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03836157
Title Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
Recruitment Withdrawn
Gender female
Phase Phase II
Variant Requirements No
Sponsors University of Oklahoma

endometrial carcinoma


Bevacizumab + Mirvetuximab Soravtansine

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.